PE20040120A1 - Derivados de quinolina como antagonistas de npy - Google Patents
Derivados de quinolina como antagonistas de npyInfo
- Publication number
- PE20040120A1 PE20040120A1 PE2003000111A PE2003000111A PE20040120A1 PE 20040120 A1 PE20040120 A1 PE 20040120A1 PE 2003000111 A PE2003000111 A PE 2003000111A PE 2003000111 A PE2003000111 A PE 2003000111A PE 20040120 A1 PE20040120 A1 PE 20040120A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ring
- quinolin
- pyrrolidin
- methyl
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE QUINOLINA COMO ANTAGONISTAS DEL NEUROPEPTIDO Y (NPY), DE FORMULA I DONDE R1 Y R2 SON HIDROGENO, ALQUILO, CICLOALQUILO, CICLOALQUILALQUILO, ALQUILCARBONILO, CICLOALQUILCARBONILO, ARILO, ARALQUILO, ENTRE OTROS; O JUNTOS CON EL ATOMO DE N SON UN ANILLO HETEROCICLICO DE 5-10 ESLABONES QUE PUEDEN TENER UN SEGUNDO HETEROATOMO COMO N U O, Y ESTE ANILLO PUEDE TENER UNO O VARIOS SUSTITUYENTES COMO ALQUILO O ALCOXI; R3 ES HIDROGENO, ALQUILO, AMINO O HALOGENO; R4 ES HIDROGENO, HALOGENO, HETEROCICLILO, AMINO O ALQUILO; A ES UN ANILLO HETEROCICLICO SATURADO DE 5 A 7 ESLABONES QUE CONTIENE UN N QUE ESTA UNIDO AL ANILLO QUINOLINA Y PUEDE TENER UN SEGUNDO HETEROATOMO COMO O, S O N, Y ESTA EVENTUALMENTE SUSTITUIDOS DE UNA A TRES VECES POR ALQUILO, ALCOXI, HIDROXI, AMINO, ACETILAMINO, CIANO, HIDROXIALQUILO, ALCOXIALQUILO,ENTRE OTROS.SON COMPUESTOS PREFERIDOS: (2-METIL-4-PIRROLIDIN-1-IL-QUINOLIN-7-IL)-AMIDA DEL ACIDO CICLOPROPANOCARBOXILICO, 2,2-DIMETIL-N-(2-METIL-4-PIRROLIDIN-1-IL-QUINOLIN-7-IL)-PROPIONAMIDA, 4-(2-METIL-4-PIRROLIDIN-1-IL-QUINOLIN-7-ILAMINO)-BENZONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE OBTENCION DEL COMPUESTO Y A UNA COMPOSICION FARMACEUTICA .EL COMPUESTO PUEDE SER USADO PARA EL TRATAMIENTO Y PROFILAXIS DE LA ARTRITIS,ENFERMEDADES CARDIOVASCULARES,DIABETES,FALLO RENAL,TRANSTORNOS DE COMIDA Y OBESIDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02001967 | 2002-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040120A1 true PE20040120A1 (es) | 2004-03-06 |
Family
ID=27635782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000111A PE20040120A1 (es) | 2002-02-04 | 2003-01-31 | Derivados de quinolina como antagonistas de npy |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6696467B2 (es) |
| EP (1) | EP1474145B1 (es) |
| JP (1) | JP4216196B2 (es) |
| KR (1) | KR100659428B1 (es) |
| CN (1) | CN100383124C (es) |
| AR (1) | AR038249A1 (es) |
| AT (1) | ATE392897T1 (es) |
| AU (1) | AU2003205679B2 (es) |
| BR (1) | BR0307441A (es) |
| CA (1) | CA2473181A1 (es) |
| DE (1) | DE60320529T2 (es) |
| ES (1) | ES2304498T3 (es) |
| MX (1) | MXPA04007502A (es) |
| PE (1) | PE20040120A1 (es) |
| PL (1) | PL372295A1 (es) |
| RU (1) | RU2298002C2 (es) |
| TW (1) | TW200400032A (es) |
| UY (1) | UY27646A1 (es) |
| WO (1) | WO2003066055A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| JP2004110367A (ja) * | 2002-09-18 | 2004-04-08 | Hitachi Ltd | 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム |
| US7317025B2 (en) | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
| DE602004031037D1 (de) | 2003-11-19 | 2011-02-24 | Array Biopharma Inc | Heterocyclische inhibitoren von mek |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| CA2624294A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| HUE034298T2 (en) * | 2007-05-17 | 2018-02-28 | Helperby Therapeutics Ltd | Use of 4- (Pyrrolidin-1-yl) quinoline derivatives to kill clinically latent microorganisms |
| WO2010056865A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
| IN2012DN00471A (es) * | 2009-06-29 | 2015-06-05 | Agios Pharmaceuticals Inc | |
| AU2011336875B2 (en) * | 2010-12-03 | 2016-09-01 | Corteva Agriscience Llc | Processes for the preparation of enamines |
| RU2612959C2 (ru) | 2011-02-18 | 2017-03-14 | АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи | Аминоиндановые соединения и их применение при лечении боли |
| CA2839703A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| MY157429A (en) | 2011-06-24 | 2016-06-15 | Amgen Inc | Trpm8 antagonists and their use in treatments |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| EP3377482B1 (en) * | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| HRP20221279T1 (hr) | 2016-07-14 | 2022-12-23 | Crinetics Pharmaceuticals, Inc. | Modulatori somatostatina i njihove uporabe |
| TWI774767B (zh) * | 2017-05-12 | 2022-08-21 | 瑞士商多蒂孔股份有限公司 | 茚烷衍生物及其在有機電子產品的用途 |
| AR112461A1 (es) | 2017-07-24 | 2019-10-30 | Vitae Pharmaceuticals Inc | PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AU2018319016B2 (en) * | 2017-08-17 | 2023-08-31 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
| HUE059184T2 (hu) * | 2018-01-17 | 2022-10-28 | Crinetics Pharmaceuticals Inc | Szomatosztatin modulátorok elõállításának folyamata |
| RU2702648C1 (ru) * | 2019-07-11 | 2019-10-09 | федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» | 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью |
| AU2021341936A1 (en) | 2020-09-09 | 2023-05-25 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| CA2133620A1 (en) * | 1993-10-28 | 1995-04-29 | Werner Hofheinz | Aminoquinoline derivatives |
| US5552411A (en) * | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| PT1105122E (pt) | 1998-08-14 | 2005-08-31 | Hoffmann La Roche | Composicoes farmaceuticas que contem inibidores de lipase |
| JP3761783B2 (ja) | 1998-08-14 | 2006-03-29 | エフ．ホフマン−ラ ロシュ アーゲー | リパーゼ阻害剤とキトサンを含む製薬学的組成物 |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| DE10064105A1 (de) * | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| DE60225274T2 (de) * | 2001-05-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Chinolinderivate als liganden für den neuropeptid-y-rezeptor |
-
2003
- 2003-01-27 CA CA002473181A patent/CA2473181A1/en not_active Abandoned
- 2003-01-27 AU AU2003205679A patent/AU2003205679B2/en not_active Ceased
- 2003-01-27 DE DE60320529T patent/DE60320529T2/de not_active Expired - Fee Related
- 2003-01-27 CN CNB038032805A patent/CN100383124C/zh not_active Expired - Fee Related
- 2003-01-27 JP JP2003565479A patent/JP4216196B2/ja not_active Expired - Fee Related
- 2003-01-27 MX MXPA04007502A patent/MXPA04007502A/es active IP Right Grant
- 2003-01-27 BR BR0307441-2A patent/BR0307441A/pt not_active IP Right Cessation
- 2003-01-27 WO PCT/EP2003/000777 patent/WO2003066055A1/en active IP Right Grant
- 2003-01-27 RU RU2004126936/04A patent/RU2298002C2/ru not_active IP Right Cessation
- 2003-01-27 PL PL03372295A patent/PL372295A1/xx not_active Application Discontinuation
- 2003-01-27 KR KR1020047012036A patent/KR100659428B1/ko not_active IP Right Cessation
- 2003-01-27 EP EP03702533A patent/EP1474145B1/en not_active Expired - Lifetime
- 2003-01-27 AT AT03702533T patent/ATE392897T1/de not_active IP Right Cessation
- 2003-01-27 ES ES03702533T patent/ES2304498T3/es not_active Expired - Lifetime
- 2003-01-30 TW TW092102218A patent/TW200400032A/zh unknown
- 2003-01-31 AR ARP030100304A patent/AR038249A1/es not_active Application Discontinuation
- 2003-01-31 PE PE2003000111A patent/PE20040120A1/es not_active Application Discontinuation
- 2003-02-03 UY UY27646A patent/UY27646A1/es not_active Application Discontinuation
- 2003-02-04 US US10/358,006 patent/US6696467B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005523901A (ja) | 2005-08-11 |
| BR0307441A (pt) | 2005-01-04 |
| MXPA04007502A (es) | 2004-11-10 |
| CA2473181A1 (en) | 2003-08-14 |
| US6696467B2 (en) | 2004-02-24 |
| AU2003205679A1 (en) | 2003-09-02 |
| KR20040081484A (ko) | 2004-09-21 |
| WO2003066055A1 (en) | 2003-08-14 |
| TW200400032A (en) | 2004-01-01 |
| KR100659428B1 (ko) | 2006-12-19 |
| US20030153553A1 (en) | 2003-08-14 |
| PL372295A1 (en) | 2005-07-11 |
| ES2304498T3 (es) | 2008-10-16 |
| EP1474145B1 (en) | 2008-04-23 |
| RU2298002C2 (ru) | 2007-04-27 |
| JP4216196B2 (ja) | 2009-01-28 |
| ATE392897T1 (de) | 2008-05-15 |
| RU2004126936A (ru) | 2005-10-10 |
| DE60320529T2 (de) | 2009-06-10 |
| AU2003205679B2 (en) | 2006-06-29 |
| CN100383124C (zh) | 2008-04-23 |
| DE60320529D1 (de) | 2008-06-05 |
| EP1474145A1 (en) | 2004-11-10 |
| AR038249A1 (es) | 2005-01-05 |
| CN1627945A (zh) | 2005-06-15 |
| UY27646A1 (es) | 2003-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040120A1 (es) | Derivados de quinolina como antagonistas de npy | |
| PE20080075A1 (es) | Compuestos fenil amido heterociclicos condensados | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| PE20041016A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20030603A1 (es) | Derivados de quinolina | |
| CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
| PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
| PE20040780A1 (es) | Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| PE20080401A1 (es) | DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS | |
| PE20050090A1 (es) | Indol-3-carboxamidas como activadores de glocoquinasa | |
| PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| PA8581401A1 (es) | Compuestos de imedazopiridina como agonistas del receptor 5-ht4 | |
| PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| PE20050079A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
| PE20060273A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 | |
| ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |